Roche Holding AG (RO.SW) Stock Analysis & Winston Score

Roche is a Swiss healthcare company that makes medicines and medical tests. Its pharmaceutical division sells treatments for cancer, multiple sclerosis, and rare diseases, while its diagnostics division makes lab equipment and tests used by hospitals and clinics worldwide. Roche is one of the largest biotech and diagnostics companies in the world, and it owns well-known cancer drugs like Herceptin, Avastin, and Rituxan. Roche makes money by selling prescription drugs directly to hospitals and healthcare systems, and by selling diagnostic instruments and the consumable test kits that run on them. The company operates globally, with strong revenue from the United States, Europe, and Japan, and generates roughly 60 billion Swiss francs in annual sales. Its main competitive advantage is its combined drug-and-diagnostics model, which few rivals can match at scale. The biggest risk Roche faces is patent expiration on several blockbuster drugs, which has already allowed cheaper biosimilar competitors to eat into sales.